ClinicalTrials.gg
CompletedNCT03611751POETYK-PSO-2Updated Dec 20, 2022Results posted

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 3 interventional study of BMS-986165 and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 205 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,020
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
4th of 26
1,020 · median 102
Started
2018
with 2 others
Phase 3
9 of 26
4 open now
Registered
6th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 4th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 6th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Plaque psoriasis for at least 6 months
  • Moderate to severe disease
  • Candidate for phototherapy or systemic therapy

Exclusion criteria

Exclusion Criteria:

  • Other forms of psoriasis
  • History of recent infection
  • Prior exposure to BMS-986165 or active comparator

Other protocol defined inclusion/exclusion criteria could apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,020 participants (actual)

Study arms

  • Experimental
    BMS-986165

    BMS-986165 oral administration

    Drug: BMS-986165

  • Placebo comparator
    Placebo

    Placebo oral administration

    Other: Placebo

  • Active comparator
    Active comparator

    Active comparator oral administration

    Drug: Apremilast

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)

    The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least a 2-point improvement from baseline using the non-responder imputation (NRI) method. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Week 16

  2. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)

    The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 90)

    The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Baseline and Week 16

  2. The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 100)

    The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the response as a number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Baseline and Week 16

  3. The Number of Participants With a Static Physician Global Assessment Score of 0 at Week 16 (sPGA 0)

    The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 using the non-responder imputation (NRI) method. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Week 16

  4. Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score at Week 16

    PSSD assesses the severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding). The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Both symptom and sign scores are derived by averaging the questions and multiplying by 10. A total PSSD score ranging 0-100 will be derived from taking the average of the symptom and sign scores. 0 represents the least severe symptom/sign and 100 represents the most severe. Baseline is defined as the measurement at the randomization visit (Week 0). A modified observation carried forward (mBOCF) approach will be used for missing data. The baseline observation will be carried forward for participants who discontinue study treatment for all analysis weeks after the assessment time point of discontinuation due to lack of efficacy and AEs.

    Time frame: Baseline and Week 16

  5. Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Week 16

    Psoriasis Symptoms and Signs Diary (PSSD) is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0 to 10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable) where the symptoms summary score is derived from the average of the scores. A higher score indicates more severe disease. PSSD 0 is the response as a number of participants who experience a PSSD symptom score that determines psoriasis severity as 0 among participants with a baseline PSSD symptom score \>= 1 using the non-responder imputation (NRI) method.

    Time frame: Week 16

  6. The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)

    The scalp specific Physician's Global Assessment (ss-PGA) evaluates scalp lesions in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease. ss-PGA 0/1 is the response as a number of participants who experience a ss-PGA score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline ss-PGA score ≥3 . Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Week 16

  7. The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)

    The DLQI is a participant-reported quality of life index which consists of 10 questions concerning how much skin problems affect symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 where 0 = not at all, 1 =a little, 2 = a lot, or 3 = very much. The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). DLQI 0/1 is the number of participants with a score of 0 or 1 among participants with a baseline DLQI score ≥2. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Week 16

  8. The Number of Participants With a Physician Global Assessment- Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PGA-F 0/1)

    The Physician Global Assessment- Fingernails (PGA-F) evaluates the overall condition of the fingernails and is rated on a 5-point scale:0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. PGA-F 0/1 is the response as a number of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score \>=3. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Week 16

  9. The Number of Participants With a Palmoplantar Physician's Global Assessment (Pp-PGA) Score of 0 or 1 at Week 16 (Pp-PGA 0/1)

    The palmoplantar Physician's Global Assessment (pp-PGA) score evaluates palmoplantar (including finger and toe surfaces) psoriasis lesions based on overall severity by investigator, then scored on the following 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe. pp-PGA 0/1 is the number of participants with a score of 0 or 1 among participants with a baseline pp-PGA score ≥ 3.

    Time frame: Week 16

  10. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)

    The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Baseline and Week 16

  11. The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)

    The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0/1 is the number of participants with a sPGA score of 0 or 1 with at least a 2-point improvement from baseline. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

    Time frame: Week 16

  12. Time to Relapse Until Week 52 Among Week 24 PASI 75 Responders

    Relapse is defined as 50% loss or greater of Week 24 PASI percent improvement from baseline. The PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity.

    Time frame: From Week 24 to Week 52 (up to approximately 28 weeks)

  13. The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (sPGA 0/1)

    The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0/1 is the number of participants with a sPGA score of 0 or 1. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

    Time frame: Week 24

  14. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (PASI 75)

    The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

    Time frame: Baseline and Week 24

  15. The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)

    The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

    Time frame: Baseline and week 24

07

Results

Posted Dec 20, 2022

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneBMS-986165PlaceboApremilast
Started511255254
Completed510254254
Not completed110
Withdrew: Randomized but not treated110
Treatment Week 0 - Week 16
Participant flow — Treatment Week 0 - Week 16
MilestoneBMS-986165PlaceboApremilast
Started510254254
Completed456212217
Not completed544237
Withdrew: Adverse event11712
Withdrew: Lack of efficacy694
Withdrew: Lost to follow-up562
Withdrew: Non-compliance with protocol521
Withdrew: Withdrawal by subject1499
Withdrew: Other reasons1397
Withdrew: Pregnancy001
Withdrew: Death001
Treatment Week 16 - Week 24
Participant flow — Treatment Week 16 - Week 24
MilestoneBMS-986165PlaceboApremilast
Started6670217
Completed6420208
Not completed2509
Withdrew: Adverse event702
Withdrew: Lack of efficacy801
Withdrew: Lost to follow-up200
Withdrew: Non-compliance with protocol301
Withdrew: Withdrawal by subject201
Withdrew: Other reasons203
Withdrew: Pregnancy101
Treatment Week 24 - Week 52
Participant flow — Treatment Week 24 - Week 52
MilestoneBMS-986165PlaceboApremilast
Started6042470
Completed5352140
Not completed69330
Withdrew: Adverse event1470
Withdrew: Lack of efficacy880
Withdrew: Lost to follow-up940
Withdrew: Non-compliance with protocol200
Withdrew: Withdrawal by subject860
Withdrew: Other reasons2870
Withdrew: Pregnancy010

Outcome measures

PrimaryThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)

The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity. sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least a 2-point improvement from baseline using the non-responder imputation (NRI) method. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)
ParticipantsBMS-986165Placebo
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)25322
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 10.55 · 95% CI 6.54 to 17.00
PrimaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)

The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)
ParticipantsBMS-986165Placebo
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)27124
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 10.49 · 95% CI 6.65 to 16.55
SecondaryThe Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 90)

The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 90)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 90)138746
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 11.42 · 95% CI 5.45 to 23.93
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0046 · Odds ratio (or): 1.74 · 95% CI 1.18 to 2.56
SecondaryThe Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 100)

The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the response as a number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 100)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index Score at Week 16 (PASI 100)52311
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 9.21 · 95% CI 2.89 to 29.40
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0051 · Odds ratio (or): 2.55 · 95% CI 1.30 to 5.00
SecondaryThe Number of Participants With a Static Physician Global Assessment Score of 0 at Week 16 (sPGA 0)

The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 using the non-responder imputation (NRI) method. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician Global Assessment Score of 0 at Week 16 (sPGA 0)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants With a Static Physician Global Assessment Score of 0 at Week 16 (sPGA 0)80316
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 14.44 · 95% CI 4.62 to 45.11
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 2.85 · 95% CI 1.61 to 5.03
SecondaryChange From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score at Week 16

PSSD assesses the severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding). The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). Both symptom and sign scores are derived by averaging the questions and multiplying by 10. A total PSSD score ranging 0-100 will be derived from taking the average of the symptom and sign scores. 0 represents the least severe symptom/sign and 100 represents the most severe. Baseline is defined as the measurement at the randomization visit (Week 0). A modified observation carried forward (mBOCF) approach will be used for missing data. The baseline observation will be carried forward for participants who discontinue study treatment for all analysis weeks after the assessment time point of discontinuation due to lack of efficacy and AEs.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score at Week 16
Score on a scaleBMS-986165PlaceboApremilast
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score at Week 16-28.9 ± 25.22-4.2 ± 19.58-21.5 ± 25.44
Statistical analysis
  • BMS-986165 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (net): -23.6 · 95% CI -26.9 to -20.3
  • BMS-986165 vs Apremilast · ANCOVA · p = <0.0001 · Mean difference (net): -7.2 · 95% CI -10.5 to -3.9
SecondaryPsoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Week 16

Psoriasis Symptoms and Signs Diary (PSSD) is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. The PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participant-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0 to 10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable) where the symptoms summary score is derived from the average of the scores. A higher score indicates more severe disease. PSSD 0 is the response as a number of participants who experience a PSSD symptom score that determines psoriasis severity as 0 among participants with a baseline PSSD symptom score \>= 1 using the non-responder imputation (NRI) method.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Week 16
ParticipantsBMS-986165PlaceboApremilast
Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Week 1635310
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0005 · Odds ratio (or): 6.40 · 95% CI 1.94 to 21.15
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0928 · Odds ratio (or): 1.82 · 95% CI 0.89 to 3.71
SecondaryThe Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)

The scalp specific Physician's Global Assessment (ss-PGA) evaluates scalp lesions in terms of clinical signs of redness, thickness, and scaliness and scored on the following 5-point ss-PGA scale: 0 = absence of disease, 1 = very mild disease, 2 = mild disease, 3 = moderate disease, 4 = severe disease. ss-PGA 0/1 is the response as a number of participants who experience a ss-PGA score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline ss-PGA score ≥3 . Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)1823061
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 6.85 · 95% CI 4.34 to 10.81
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.63 · 95% CI 1.77 to 3.91
SecondaryThe Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)

The DLQI is a participant-reported quality of life index which consists of 10 questions concerning how much skin problems affect symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week. Each question is scored on a scale of 0 to 3 where 0 = not at all, 1 =a little, 2 = a lot, or 3 = very much. The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). DLQI 0/1 is the number of participants with a score of 0 or 1 among participants with a baseline DLQI score ≥2. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)
ParticipantsBMS-986165Placebo
The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)18624
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.38 · 95% CI 3.42 to 8.47
SecondaryThe Number of Participants With a Physician Global Assessment- Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PGA-F 0/1)

The Physician Global Assessment- Fingernails (PGA-F) evaluates the overall condition of the fingernails and is rated on a 5-point scale:0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe. PGA-F 0/1 is the response as a number of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score \>=3. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Physician Global Assessment- Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PGA-F 0/1)
ParticipantsBMS-986165Placebo
The Number of Participants With a Physician Global Assessment- Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PGA-F 0/1)143
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0621 · Odds ratio (or): 3.21 · 95% CI 0.88 to 11.79
SecondaryThe Number of Participants With a Palmoplantar Physician's Global Assessment (Pp-PGA) Score of 0 or 1 at Week 16 (Pp-PGA 0/1)

The palmoplantar Physician's Global Assessment (pp-PGA) score evaluates palmoplantar (including finger and toe surfaces) psoriasis lesions based on overall severity by investigator, then scored on the following 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; and 4 = severe. pp-PGA 0/1 is the number of participants with a score of 0 or 1 among participants with a baseline pp-PGA score ≥ 3.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Palmoplantar Physician's Global Assessment (Pp-PGA) Score of 0 or 1 at Week 16 (Pp-PGA 0/1)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants With a Palmoplantar Physician's Global Assessment (Pp-PGA) Score of 0 or 1 at Week 16 (Pp-PGA 0/1)1848
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = 0.6692 · Odds ratio (or): 0.64 · 95% CI 0.06 to 7.46
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.3793 · Odds ratio (or): 0.32 · 95% CI 0.02 to 5.56
SecondaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)

The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. The PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)271101
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0004 · Odds ratio (or): 1.76 · 95% CI 1.29 to 2.41
SecondaryThe Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)

The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0/1 is the number of participants with a sPGA score of 0 or 1 with at least a 2-point improvement from baseline. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 16 or who have missing Week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)
ParticipantsBMS-986165Apremilast
The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)25386
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.01 · 95% CI 1.45 to 2.78
SecondaryTime to Relapse Until Week 52 Among Week 24 PASI 75 Responders

Relapse is defined as 50% loss or greater of Week 24 PASI percent improvement from baseline. The PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity.

Time frame:
From Week 24 to Week 52 (up to approximately 28 weeks)
Reported as:
Median · Days
Time to Relapse Until Week 52 Among Week 24 PASI 75 Responders
DaysBMS-986165PlaceboApremilast
Time to Relapse Until Week 52 Among Week 24 PASI 75 RespondersNA (NA to NA)NA (NA to NA)197.0 (125.0 to NA)
Statistical analysis
  • BMS-986165 vs Placebo · Log Rank · p = <0.0001
SecondaryThe Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (sPGA 0/1)

The sPGA is a 5-point scale average assessment of all psoriatic lesions graded for erythema, scale, and induration. The sPGA measure determines psoriasis severity at a single point in time (without taking into account the baseline disease condition) as: clear (0), almost clear (1), mild (2), moderate (3), or severe (4). The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. sPGA 0/1 is the number of participants with a sPGA score of 0 or 1. Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

Time frame:
Week 24
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (sPGA 0/1)
ParticipantsBMS-986165Apremilast
The Number of Participants With a Static Physician Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (sPGA 0/1)25175
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.47 · 95% CI 1.78 to 3.43
SecondaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (PASI 75)

The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

Time frame:
Baseline and Week 24
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (PASI 75)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremalist at Week 24 (PASI 75)29696
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.44 · 95% CI 1.78 to 3.36
SecondaryThe Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)

The Psoriasis Area and Severity Index (PASI) is a quantitative rating scale for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. PASI is a measure of the average erythema (redness), infiltration (thickness), and desquamation (scaling) of psoriatic skin lesions (each graded on a 0-4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method. Baseline is defined as the measurement at the randomization visit (Week 0). Non-responder imputation (NRI) will be used for participants who: Discontinue treatment or study prior to Week 24 or who have missing Week 24 endpoint data for any reason.

Time frame:
Baseline and week 24
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)16450
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0001 · Odds ratio (or): 2.07 · 95% CI 1.43 to 3.01

Adverse events

Collected over Participants were assessed for All-Cause Mortality from their first dose until the study was completed (up to approximately 60 weeks). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 56 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986165 (Week 0 up to Week 16)1/511 (0.2%)8/510 (1.6%)114/510 (22.4%)
Placebo (Week 0 up to Week 16)0/255 (0%)3/254 (1.2%)61/254 (24%)
Apremilast (Week 0 up to Week 16)1/254 (0.4%)1/254 (0.4%)86/254 (33.9%)
BMS-986165 (Week 0 up to Week 52)2/834 (0.2%)24/833 (2.9%)249/833 (29.9%)
Placebo (Week 0 up to Week 52)0/502 (0%)5/501 (1%)97/501 (19.4%)
Apremilast (Week 0 up to Week 52)1/254 (0.4%)3/254 (1.2%)98/254 (38.6%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventBMS-986165 (Week 0 up to Week 16)Placebo (Week 0 up to Week 16)Apremilast (Week 0 up to Week 16)BMS-986165 (Week 0 up to Week 52)Placebo (Week 0 up to Week 52)Apremilast (Week 0 up to Week 52)
Gastrointestinal arteriovenous malformationCongenital, familial and genetic disorders0/5100/2541/2540/8330/5011/254
Gastrointestinal haemorrhageGastrointestinal disorders1/5100/2541/2541/8330/5011/254
CellulitisInfections and infestations0/5101/2540/2540/8331/5010/254
Mycoplasma infectionInfections and infestations0/5100/2540/2540/8330/5011/254
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5100/2541/2540/8330/5011/254
Ischaemic strokeNervous system disorders0/5100/2541/2540/8330/5011/254
Major depressionPsychiatric disorders0/5101/2540/2540/8331/5010/254
Ovarian cystReproductive system and breast disorders0/5100/2540/2540/8330/5011/254
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/5101/2540/2540/8331/5010/254
Peripheral artery occlusionVascular disorders0/5101/2540/2540/8331/5010/254
Most frequent other events
Most frequent other events
EventBMS-986165 (Week 0 up to Week 16)Placebo (Week 0 up to Week 16)Apremilast (Week 0 up to Week 16)BMS-986165 (Week 0 up to Week 52)Placebo (Week 0 up to Week 52)Apremilast (Week 0 up to Week 52)
NasopharyngitisInfections and infestations55/51029/25423/254133/83347/50128/254
DiarrhoeaGastrointestinal disorders24/51019/25433/25439/83322/50135/254
HeadacheNervous system disorders22/51014/25428/25445/83316/50130/254
NauseaGastrointestinal disorders7/5103/25423/25413/8336/50126/254
Upper respiratory tract infectionInfections and infestations25/51011/25414/25474/83327/50121/254

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS-986165PlaceboApremilastTotal
Mean46.9 ± 13.3747.3 ± 13.5746.4 ± 13.2846.9 ± 13.39
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986165PlaceboApremilastTotal
Female1757497346
Male336181157674
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986165PlaceboApremilastTotal
Hispanic or Latino582929116
Not Hispanic or Latino445226223894
Unknown or Not Reported80210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BMS-986165PlaceboApremilastTotal
White474232229935
Black or African American89926
Asian2481244
American Indian or Alaska Native2237
Native Hawaiian or Other Pacific Islander0000
Other3418
08

Study locations

205 sites
  • Total Skin and Beauty Dermatology Center
    Birmingham, Alabama 35205, United States
  • The Kirklin Clinic of UAB Hospital
    Birmingham, Alabama 35233, United States
  • Alliance Dermatology and Mohs Center - Phoenix
    Phoenix, Arizona 85032, United States
  • Clinical Research Consortium - Tempe
    Tempe, Arizona 85283, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • Associates in Research, Inc.
    Fresno, California 93720, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • Interspond - Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Dermatology Research Associates - Los Angeles
    Los Angeles, California 90045-3606, United States
  • LA Universal Research Center
    Los Angeles, California 90057, United States
  • Artemis Institute for Clinical Research - San Diego
    San Diego, California 92103, United States
  • University of California San Diego Health Systems
    San Diego, California 92122, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • San Luis Dermatology and Laser Clinic
    San Luis Obispo, California 93405, United States
  • Artemis Institute for Clinical Research - San Marcos
    San Marcos, California 92078, United States
  • West Coast Research
    San Ramon, California 94582, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Synexus - Santa Rosa
    Santa Rosa, California 95405, United States
  • Care Access Research - Walnut Creek
    Walnut Creek, California 94598, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Skin Care Research
    Boca Raton, Florida 33486, United States
  • ERN - Accel Research - Avail
    DeLand, Florida 32720, United States
  • Interspond - Savin Medical Group
    Miami Lakes, Florida 33014, United States
  • Synexus Clinical Research - Saint Petersburg
    Pinellas Park, Florida 33781, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Precision Clinical Research - Corporate Office
    Sunrise, Florida 33351, United States
  • Precision Clinical Research - Corporate Office
    Tamarac, Florida 33351, United States
  • Moore Clinical Research - South Tampa
    Tampa, Florida 33609, United States
  • University of South Florida/USF Health
    Tampa, Florida 33612, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Marietta Dermatology & The Skin Cancer Center
    Marietta, Georgia 30060, United States
  • Advanced Clinical Research - Idaho
    Meridian, Idaho 83642, United States
  • Glazer Dermatology
    Buffalo Grove, Illinois 60089, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dermatology Center of Northwest Indiana
    Crown Point, Indiana 46307, United States
  • Synexus - Evansville South
    Evansville, Indiana 47714, United States
  • Dawes Fretzin Dermatology Group
    Indianapolis, Indiana 46250, United States
  • Skin Sciences
    Louisville, Kentucky 40217, United States
  • Advanced Medical Research
    Lacombe, Louisiana 70445, United States
  • Shondra L. Smith, M.D.
    Lake Charles, Louisiana 70605-1213, United States
  • DelRicht Research - New Orleans - Prytania Street
    New Orleans, Louisiana 70115, United States
  • Ora
    Andover, Massachusetts 01810, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Brigham Dermatology Associates
    Boston, Massachusetts 02115, United States
  • A. Alfred Taubman Health Care Center
    Ann Arbor, Michigan 48109, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Washington University School of Medicine - West County Dermatology
    Creve Coeur, Missouri 63141, United States
  • Healthcare Research Network - Hazelwood
    Hazelwood, Missouri 63042, United States
  • Clinical Research Consortium - Las Vegas
    Las Vegas, Nevada 89119, United States
  • ActivMed Practices and Research - Portsmouth
    Portsmouth, New Hampshire 03801, United States
  • Windsor Dermatology
    East Windsor, New Jersey 08520, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • DermResearch Center of New York
    Stony Brook, New York 11790, United States
  • PMG Research of Cary
    Cary, North Carolina 27615, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Wilmington Dermatology Center
    Wilmington, North Carolina 28405, United States
  • Synexus - Cincinnati
    Cincinnati, Ohio 45249, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • ClinOhio Research Services
    Columbus, Ohio 43213, United States
  • Wright State Research Institute
    Fairborn, Ohio 45324, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Unity Clinical Research
    Oklahoma City, Oklahoma 73118, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Dermatology and Skin Surgery Center - Exton
    Exton, Pennsylvania 19341, United States
  • Paddington Testing Company
    Philadelphia, Pennsylvania 19103, United States
  • Synexus
    Greer, South Carolina 29651, United States
  • Coastal Carolina Research Center - Mount Pleasant
    Mount Pleasant, South Carolina 29464, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Rivergate Dermatology - Main Office
    Goodlettsville, Tennessee 37072, United States
  • Clinical Research Solutions - Jackson
    Jackson, Tennessee 38305, United States
  • Dermatology Associates of Knoxville
    Knoxville, Tennessee 37917, United States
  • The Skin Wellness Center
    Knoxville, Tennessee 37922, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • DermResearch
    Austin, Texas 78759, United States
  • Bellaire Dermatology
    Bellaire, Texas 77401, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Synexus - Dallas
    Dallas, Texas 75234, United States
  • Progressive Clinical Research - San Antonio
    San Antonio, Texas 78213-2250, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Interspond - Houston Center for Clinical Research
    Sugar Land, Texas 77479, United States
  • West Virginia University
    Morgantown, West Virginia 26501, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Woden Dermatology
    Phillip, Australian Capital Territory 2606, Australia
  • Holdsworth House Medical Practice
    Darlinghurst, New South Wales 2010, Australia
  • St. George Dermatology & Skin Care Centre
    Kogarah, New South Wales 2217, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research
    Woolloongabba, Queensland 4102, Australia
  • North Eastern Health Specialists
    Hectorville, South Australia 5073, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Skin and Cancer Foundation
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia

Showing the first 100 of 205 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Nov 2020, 28 months.

Results were first posted in Dec 2022, 2 years after primary completion. A results delay was requested in Nov 2021.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 28 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2018
First posted
Aug 2, 2018
StartActual
Jul 26, 2018
Primary completionActual
Nov 29, 2020
CompletionActual
Nov 30, 2020
Results delay requested
Nov 29, 2021
Results first posted
Dec 20, 2022
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03611751
Responsible party
Sponsor
First posted
Aug 2, 2018
Start date
Jul 26, 2018
Primary completion
Nov 29, 2020
Completion
Nov 30, 2020
Results posted
Dec 20, 2022
Last update
Dec 20, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion